---

IMPORTANT DISCLAIMER: All content on this page is intended strictly for educational and scientific research reference purposes. Tirzepatide offered by Palmetto Peptides is sold exclusively for in vitro laboratory research use only. It is not intended for human consumption, self-administration, veterinary use, or any application outside of controlled laboratory settings. Nothing on this page constitutes medical advice, and Palmetto Peptides does not advocate for the use of any research peptide outside of a licensed research context. Researchers are solely responsible for compliance with all applicable laws and regulations.

---

Palmetto Peptides Complete Guide to the Research Peptide Tirzepatide

Last Updated: March 19, 2025 | Author: Palmetto Peptides Research Team

---

The short answer: Tirzepatide is a synthetic 39-amino acid research peptide that simultaneously engages both the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 (glucagon-like peptide-1) receptor. Because of this dual-receptor activity, it is described in the scientific literature as a "twincretin" — a single molecule that mimics the actions of two distinct incretin hormones. Published research has studied its effects on glucose metabolism, body weight, cardiovascular markers, hepatic function, and more. This guide compiles what the peer-reviewed literature currently says about tirzepatide for researchers who need a thorough, well-sourced reference.

---

Table of Contents

1. What Is Tirzepatide?
2. Molecular Structure and Chemical Properties
3. Mechanism of Action: The Dual Incretin System
4. GIP vs. GLP-1: Understanding the Two Pathways
5. How Tirzepatide Compares to Selective GLP-1 Agonists in the Literature
6. SURPASS Clinical Trial Program Summary
7. SURMOUNT Trial Program Summary
8. Tirzepatide and Cardiovascular Research
9. Tirzepatide and Hepatic Research
10. Tirzepatide and Neurological Research
11. Pharmacokinetics: Half-Life and Albumin Binding
12. Observed Safety Profile in Clinical Literature
13. Tirzepatide vs. Other Research Peptides: A Quick Reference Table
14. Related Peptide Products at Palmetto Peptides
15. Frequently Asked Questions
16. References

---

What Is Tirzepatide?

Tirzepatide (research designation: LY3298176) is a first-in-class synthetic peptide that functions as a dual agonist at both the GIP receptor and the GLP-1 receptor. It was originally developed by Eli Lilly and Company and has been the subject of one of the most extensive peptide clinical trial programs in recent pharmaceutical history.

The compound was first disclosed in patents filed in 2016, and its synthesis relies on standard solid-phase peptide synthesis techniques. Its molecular design borrows from the natural sequence of human GIP while also incorporating amino acid residues shared with GLP-1 and exendin-4 (a peptide found in the saliva of Heloderma suspectum, the Gila monster, which later became the basis for exenatide). Three amino acid positions in tirzepatide are unique to this molecule and are not found in any native peptide.

In the published scientific literature, tirzepatide is notable for being the first synthetic peptide to achieve simultaneous, sustained dual engagement of both incretin hormone receptors in a single molecule. This is distinct from earlier approaches that required co-administration of two separate peptides to achieve similar receptor coverage.

For researchers interested in acquiring tirzepatide for laboratory use, visit our Tirzepatide Research Peptide product page for current specifications and purity data.

---

Molecular Structure and Chemical Properties

Understanding tirzepatide's structure is essential for any researcher working with this peptide. Here is what the literature tells us about its composition.

Amino Acid Sequence and Length

Tirzepatide consists of 39 amino acids arranged in a linear sequence. The starting framework is the native human GIP hormone sequence, from which tirzepatide retains nine homologous amino acids. An additional ten amino acids are shared between GIP and GLP-1, and four correspond to positions in the GLP-1 molecule specifically. Ten amino-terminal amino acids are identical to those found in exendin-4. Three positions are unique to tirzepatide.

The molecule also incorporates two aminoisobutyric acid (Aib) residues at positions 2 and 13. Position 2 is a recognized cleavage site for dipeptidyl peptidase-4 (DPP-4), so the Aib substitution there directly protects tirzepatide from rapid enzymatic degradation in physiological conditions. This is a common and well-documented structural strategy in synthetic peptide design.

Fatty Acid Modification and Albumin Binding

What really separates tirzepatide from shorter-lived incretin analogs is its C20 fatty diacid moiety — specifically, eicosanedioic acid. This fatty diacid is connected to the lysine residue side chain via a glutamic acid spacer and two (2-(2-aminoethoxy)ethoxy)acetic acid (mini-PEG) units.

This arrangement gives tirzepatide an extremely high affinity for serum albumin. In practical terms, this means that once in circulation, tirzepatide binds reversibly to albumin, which substantially slows its clearance and extends its functional half-life far beyond that of native GIP or GLP-1. The result, as shown in pharmacokinetic studies, is a half-life profile consistent with once-weekly dosing in humans.

Molecular Weight and Solubility

Tirzepatide has a molecular weight of approximately 4,813.5 Da. For in vitro research applications, the peptide is typically supplied as a lyophilized powder with purity greater than 98% (as confirmed by HPLC and mass spectrometry). It is generally soluble in sterile water or acetic acid buffers at appropriate concentrations.

---

Mechanism of Action: The Dual Incretin System

To understand what makes tirzepatide scientifically significant, it helps to understand the incretin system first — and then see how tirzepatide works within it.

What Are Incretins?

Incretins are gut-derived hormones that are secreted in response to nutrient ingestion and act on pancreatic beta cells to stimulate insulin release in a glucose-dependent manner. The two primary incretins in humans are:

• GLP-1 (glucagon-like peptide-1) — produced by L cells in the distal small intestine and colon
• GIP (glucose-dependent insulinotropic polypeptide) — produced by K cells in the proximal small intestine

Together, these hormones account for a significant portion of the postprandial insulin response in healthy individuals — a phenomenon known as the "incretin effect." Research has shown that in individuals with certain metabolic conditions, this incretin effect is blunted, which contributes to impaired glucose regulation.

The challenge with native incretins as therapeutic tools is their extremely short half-lives. Both GIP and GLP-1 are rapidly cleaved by DPP-4 within minutes of secretion, making them impractical as standalone research agents without structural modification.

How Tirzepatide Engages Both Receptors

Tirzepatide selectively binds to and activates both the GIPR and GLP-1R, both of which are class B G protein-coupled receptors (GPCRs). These receptors are expressed not only in pancreatic beta cells but also in many other tissues including the brain (particularly hypothalamic regions involved in appetite regulation), the cardiovascular system, adipose tissue, and the gastrointestinal tract.

Research has established that tirzepatide does not engage both receptors with equal intensity. Studies calculating receptor occupancy have found that tirzepatide shows greater engagement at the GIP receptor than at the GLP-1 receptor. This is described in the published literature as an "imbalanced" or "biased" mechanism of action.

At the GLP-1 receptor specifically, tirzepatide also demonstrates what researchers call "biased agonism" — it preferentially activates the cAMP signaling pathway over beta-arrestin recruitment. This is distinct from how native GLP-1 interacts with its receptor and may contribute to differences in the downstream effects observed between tirzepatide and selective GLP-1 receptor agonists.

Downstream Signaling Effects Studied in Research

Based on the published literature, tirzepatide's dual receptor engagement is associated with the following downstream effects that have been studied in clinical and preclinical settings:

• Glucose-dependent stimulation of insulin secretion from pancreatic beta cells
• Reduction of glucagon secretion
• Increases in adiponectin levels (an adipokine involved in glucose and lipid metabolism regulation)
• Reductions in appetite and food intake signals via central nervous system pathways
• Improvements in markers of insulin sensitivity beyond what would be expected from weight changes alone
• Modulation of lipid metabolism, including reductions in fasting triglycerides

---

GIP vs. GLP-1: Understanding the Two Pathways

One of the more interesting aspects of the scientific conversation around tirzepatide is the role of GIP. For many years, GIP was considered a therapeutic dead-end in metabolic research. Early studies showed that in individuals with type 2 diabetes, supraphysiological infusion of GIP alone produced minimal insulinotropic response, leading researchers to largely set aside GIP as a therapeutic target.

Tirzepatide essentially reopened that conversation. The hypothesis driving its development was that co-engagement of GLP-1 and GIP receptors would produce synergistic effects that neither agonist could achieve alone. This turned out to be well-supported by subsequent research. Studies have shown that co-infusion of GLP-1 and GIP results in significantly greater insulin response and glucagonostatic effect compared to administering either hormone separately.

What this tells researchers is that the GIP pathway's apparent unresponsiveness in metabolic disease may be context-dependent — and that when GLP-1 receptor signaling is also present, GIP receptor engagement appears to contribute meaningfully to the overall metabolic response.

This synergy is a central reason why tirzepatide is considered a scientifically distinct compound from earlier GLP-1 receptor agonists, and why it has attracted substantial research interest beyond its initial development context.

---

How Tirzepatide Compares to Selective GLP-1 Agonists in the Literature

Researchers frequently encounter questions about how tirzepatide compares to selective GLP-1 receptor agonists like semaglutide. The published clinical literature offers some direct comparisons.

Head-to-Head Data from the SURPASS-2 Trial

The SURPASS-2 trial was a phase 3 randomized controlled trial that compared tirzepatide (at 5 mg, 10 mg, and 15 mg doses) against semaglutide 1.0 mg weekly in participants with type 2 diabetes. It is among the most directly comparable datasets available in the peer-reviewed literature for this comparison.

Key findings from SURPASS-2 that have been published:

• All three tirzepatide dose groups showed statistically greater reductions in HbA1c compared to semaglutide 1.0 mg
• Tirzepatide at 10 mg and 15 mg showed greater body weight reductions compared to semaglutide
• A substantially higher percentage of tirzepatide-treated participants reached normoglycemia (HbA1c below 5.7%)
• The overall safety profile was generally comparable between the two agents, with gastrointestinal events being the most commonly reported adverse effects in both groups

What the Literature Says About Adiponectin

One specific biomarker difference worth noting for researchers is adiponectin. Tirzepatide treatment has been reported to increase adiponectin levels by up to 26% from baseline after 26 weeks at the 10 mg dose. Adiponectin is an adipokine that plays a role in both glucose and lipid metabolism regulation. This adiponectin effect is not as prominently reported for selective GLP-1 agonists and may relate to tirzepatide's GIP receptor engagement.

---

SURPASS Clinical Trial Program: Summary for Researchers

The SURPASS program is a series of five phase 3 clinical trials (SURPASS 1 through 5) that examined tirzepatide in individuals with type 2 diabetes. These trials represent the core published evidence base for tirzepatide's metabolic effects in humans.

SURPASS Program Overview

Trial	Comparator	Duration	Key Findings Published
SURPASS-1	Placebo	40 weeks	Tirzepatide (5/10/15 mg) reduced HbA1c by 1.87/1.89/2.07% vs. 0.04% placebo
SURPASS-2	Semaglutide 1.0 mg	40 weeks	All tirzepatide doses superior on HbA1c; 10/15 mg superior on weight
SURPASS-3	Insulin degludec	52 weeks	Tirzepatide showed greater HbA1c and weight reductions vs. insulin
SURPASS-4	Insulin glargine	52 weeks	Tirzepatide showed greater HbA1c reduction with less hypoglycemia
SURPASS-5	Insulin glargine add-on	40 weeks	Tirzepatide add-on to insulin showed greater glycemic control

Across the full SURPASS program, tirzepatide at doses of 5 to 15 mg weekly reduced HbA1c by 1.24 to 2.58 percentage points and reduced body weight by 5.4 to 11.7 kg. The proportion of participants reaching normoglycemia (HbA1c under 5.7%) ranged from 23.0% to 62.4% depending on dose and trial. Between 20.7% and 68.4% of participants across trials lost more than 10% of their baseline body weight.

These figures are documented in the peer-reviewed literature and are provided here as a research reference. They reflect results in clinical trial populations under controlled conditions.

---

SURMOUNT Trial Program: Tirzepatide and Weight-Related Research

While the SURPASS program focused on type 2 diabetes populations, the SURMOUNT program examined tirzepatide in individuals with obesity or overweight without diabetes. This distinction matters for researchers who are studying metabolic peptides in non-diabetic models.

SURMOUNT-1 Key Data

SURMOUNT-1 was a 72-week phase 3 trial. Participants receiving tirzepatide 5 mg, 10 mg, and 15 mg once weekly showed mean body weight reductions of 16.5%, 21.4%, and 22.4%, respectively, compared to 2.4% in the placebo group.

The proportion of participants achieving 20% or more body weight reduction was 15%, 39.5%, and 55.8% for the three tirzepatide dose groups respectively, compared to 1.3% in the placebo group.

SURMOUNT-1 also included post-hoc analyses examining fasting biomarkers related to insulin sensitivity and beta-cell function. These analyses found improvements in both parameters that were, in some cases, beyond what would be explained by weight loss alone.

China-Specific SURMOUNT Data

A separate 52-week study conducted at 29 centers in China randomized 210 participants to tirzepatide 10 mg, 15 mg, or placebo alongside lifestyle intervention. Mean body weight reductions were 13.6% and 17.5% for the 10 mg and 15 mg groups respectively, versus 2.3% in the placebo group. More than 85% of participants in both tirzepatide groups achieved at least 5% weight loss, compared to 29.3% in the placebo group. Gastrointestinal adverse events were the most common and were mostly mild to moderate in severity.

---

Tirzepatide and Cardiovascular Research

Cardiovascular effects represent one of the more active areas of tirzepatide research beyond glycemia and weight. For researchers working in this space, here is what the published literature currently shows.

SUMMIT Trial: Heart Failure with Preserved Ejection Fraction

The SUMMIT trial examined tirzepatide in participants with heart failure with preserved ejection fraction (HFpEF) and obesity. A cardiac MRI substudy within SUMMIT enrolled 175 patients, of whom 106 completed imaging at both baseline and 52 weeks. Tirzepatide significantly reduced left ventricular mass and paracardiac adipose tissue compared to placebo. Reductions in these parameters were associated with weight loss and may underlie the reduction in HFpEF-related events observed in the main trial.

Cardiovascular Biomarker Data

Post-hoc analyses from the SURPASS trials have examined several cardiovascular biomarkers. Published data show that tirzepatide treatment was associated with reductions in fasting triglycerides, improvements in HDL cholesterol, and reductions in blood pressure across multiple studies. A specific post-hoc analysis found that tirzepatide improved cardiovascular risk biomarkers in participants with type 2 diabetes at all three doses studied.

SURPASS-CVOT

The SURPASS-CVOT trial is the dedicated cardiovascular outcomes trial for tirzepatide. Results from this trial, examining major adverse cardiovascular events (MACE) in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, have been eagerly anticipated by the research community. Researchers following this space should consult current PubMed listings for the most recent publications.

---

Tirzepatide and Hepatic Research

Metabolic dysfunction-associated steatohepatitis (MASH, previously known as NASH) is an area of growing research interest for incretin-based peptides. Tirzepatide has been studied in this context both preclinically and in early clinical investigations.

A proteomics, metabolomics, and lipidomics integration study in mice published in Lipids in Health and Disease explored tirzepatide's molecular mechanisms in alleviating metabolic dysfunction-associated fatty liver. The study found modulation of lipid processing pathways and metabolic intermediates relevant to hepatic steatosis. These are preclinical findings and cannot be extrapolated to humans without clinical validation.

Clinically, tirzepatide's known effects on body weight, triglycerides, insulin resistance, and liver-related biomarkers have made it a subject of investigation in MASH-related trials. The published literature in this area continues to grow, and researchers should consult the primary sources cited at the end of this guide for current findings.

---

Tirzepatide and Neurological Research

An emerging body of preclinical and early clinical research has explored GLP-1 and GIP receptor agonism in the context of neurological conditions, including neurodegenerative diseases. Both GLP-1 receptors and GIP receptors are expressed in brain regions beyond the hypothalamus, including areas associated with neuroprotection, inflammation modulation, and synaptic plasticity.

Published reviews have noted tirzepatide's potential mechanistic relevance to Alzheimer's disease and Parkinson's disease research based on its actions on inflammation pathways, oxidative stress, and insulin signaling in the brain. These are early-stage, largely preclinical observations. The current peer-reviewed literature does not support clinical conclusions in this area, but it is an active research direction that several groups are pursuing.

For laboratory researchers studying neuroinflammation, neurodegeneration, or central nervous system metabolic signaling, tirzepatide's dual receptor profile and brain-region receptor expression make it an interesting candidate for in vitro study designs.

---

Pharmacokinetics: Half-Life and Albumin Binding

Understanding the pharmacokinetics of any research peptide is critical for designing appropriate in vitro experiments. Here is what the published literature documents about tirzepatide's kinetic properties.

Why Native Incretins Have Short Half-Lives

Native GIP and GLP-1 are inactivated by DPP-4 within minutes of secretion in physiological conditions. This rapid degradation is why native incretin hormones are essentially impractical as research tools in their unmodified forms, and why synthetic analogs with protective structural modifications are used in research.

How Tirzepatide Achieves Extended Half-Life

Tirzepatide employs two structural strategies to resist rapid clearance:

1. DPP-4 resistance: The aminoisobutyric acid (Aib) substitution at position 2 blocks DPP-4 cleavage at that site, protecting the peptide from the primary enzymatic degradation pathway.

2. Albumin binding via fatty acid modification: The C20 fatty diacid moiety enables tirzepatide to bind reversibly and with high affinity to serum albumin. Albumin binding dramatically slows renal filtration and extends the effective residence time of the peptide in circulation. This strategy is well-established in long-acting peptide design and is also used in other synthetic peptides including semaglutide.

The combination of these two modifications produces a half-life that supports once-weekly dosing in human pharmacokinetic studies. Researchers working with tirzepatide in in vitro settings should account for the albumin-binding properties when designing assay conditions, particularly when albumin or serum is present in the experimental system.

---

Observed Safety Profile in Clinical Literature

Researchers reviewing tirzepatide for laboratory reference purposes should also be aware of the safety data reported in clinical trials. This information is relevant for understanding the peptide's biological activity profile, not as medical guidance.

Most Commonly Reported Adverse Events

Across the SURPASS and SURMOUNT trial programs, the most frequently reported adverse events associated with tirzepatide were gastrointestinal in nature:

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Decreased appetite
• Upper abdominal discomfort
• Abdominal pain

These effects were reported as mostly mild to moderate in severity and typically occurred during dose escalation periods. Discontinuation rates due to adverse events in the published trials were generally low.

Hypoglycemia Considerations

As a glucose-dependent mechanism (both GIP and GLP-1 stimulate insulin secretion only when glucose levels are elevated), tirzepatide showed a low intrinsic risk of hypoglycemia in trials where it was used without concomitant insulin or insulin secretagogues. When combined with insulin in the SURPASS-5 trial, hypoglycemia events were more frequent, consistent with expectations for that combination.

FDA Adverse Event Reporting System (FAERS) Analysis

A published study using FAERS data from Q2 2022 through Q4 2023 examined the real-world adverse event reporting profile for tirzepatide following its initial approval. This analysis represents a complementary signal-detection resource alongside the controlled trial data.

---

Tirzepatide vs. Other Research Peptides: Quick Reference

For researchers exploring the incretin peptide landscape, this reference table summarizes key structural and mechanistic distinctions across related peptides as documented in the literature.

Peptide	Receptor Target(s)	Amino Acids	DPP-4 Protected	Fatty Acid Modified	Approx. Half-Life
Native GLP-1	GLP-1R	30-31	No	No	~2 minutes
Native GIP	GIPR	42	No	No	~2-3 minutes
Semaglutide	GLP-1R	31	Yes (Aib at pos. 8)	Yes (C18 diacid)	~1 week
Tirzepatide	GIP R + GLP-1R	39	Yes (Aib at pos. 2, 13)	Yes (C20 diacid)	~5 days
Exendin-4 / Exenatide	GLP-1R	39	Yes (Gly at pos. 2)	No	~2-3 hours

Table reflects published structural and pharmacokinetic data. All peptides listed are for research reference purposes.

---

Related Peptide Products at Palmetto Peptides

Researchers studying incretin biology, metabolic peptides, or dual receptor agonism may also be interested in these related research peptides available through Palmetto Peptides:

• Semaglutide Research Peptide — selective GLP-1 receptor agonist; useful as a comparator in GLP-1R pathway studies
• GLP-1 (7-36) Amide — native GLP-1 fragment for reference studies in incretin biology
• GIP (1-42) — native human GIP for GIPR pathway studies
• Retatrutide — triple GIP/GLP-1/glucagon receptor agonist for research on multi-receptor incretin pharmacology
• CJC-1295 — growth hormone-releasing hormone analog; relevant for researchers studying metabolic peptide half-life extension strategies
• BPC-157 — gastroprotective research peptide for gastrointestinal model studies

For the full catalog of research peptides, visit the Palmetto Peptides Research Peptide Catalog.

---

Frequently Asked Questions

What is tirzepatide?

Tirzepatide is a synthetic 39-amino acid research peptide that acts as a dual agonist at both the GIP receptor and the GLP-1 receptor. It is sometimes called a "twincretin" in the scientific literature because it mimics the actions of both incretin hormones simultaneously. Palmetto Peptides supplies tirzepatide strictly for in vitro and laboratory research purposes.

How does tirzepatide differ from GLP-1 receptor agonists?

Unlike selective GLP-1 receptor agonists such as semaglutide, tirzepatide engages both the GIP receptor and the GLP-1 receptor. Published research indicates that tirzepatide shows a preference for GIP receptor engagement, and also demonstrates biased agonism at the GLP-1 receptor — favoring cAMP signaling over beta-arrestin recruitment.

What is the molecular structure of tirzepatide?

Tirzepatide is a 39-amino acid linear peptide based on the native human GIP hormone sequence, incorporating a C20 fatty diacid moiety attached via a glutamic acid linker to a lysine residue. This modification enables albumin binding and extends the peptide's half-life significantly compared to native incretin hormones.

What does peer-reviewed research say about tirzepatide?

Published peer-reviewed literature — including the SURPASS and SURMOUNT clinical trial series — has examined tirzepatide's effects on glycemic markers, body weight, cardiovascular biomarkers, hepatic function, and renal parameters. Researchers have also explored its effects across metabolic, neurological, and cardiovascular preclinical models.

Is tirzepatide sold by Palmetto Peptides for human use?

No. Tirzepatide offered by Palmetto Peptides is supplied exclusively for in vitro laboratory and research purposes. It is not intended for human consumption, self-administration, veterinary use, or any application outside of controlled laboratory settings.

What is tirzepatide's half-life based on published research?

Due to its C20 fatty diacid modification and DPP-4-resistant substitutions, tirzepatide has an extended half-life of approximately five days, which supports once-weekly administration in the approved pharmaceutical formulations studied in clinical trials.

What receptors does tirzepatide bind to?

Tirzepatide selectively binds to and activates both the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R), both class B GPCRs expressed in pancreatic beta cells and multiple other tissues including the brain, cardiovascular system, and adipose tissue.

Where can I buy tirzepatide for research?

Palmetto Peptides offers tirzepatide for purchase by qualified researchers for in vitro and laboratory research use only. Visit our Tirzepatide Research Peptide product page for specifications, purity certificates, and ordering information.

---

References

The following peer-reviewed sources were consulted in the preparation of this guide. Researchers are encouraged to consult primary sources directly for full methodology and data.

1. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. https://doi.org/10.1016/j.molmet.2018.09.009

2. Willard FS, Douros JD, Gabe MBN, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. https://pmc.ncbi.nlm.nih.gov/articles/PMC7526454/

3. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515. https://doi.org/10.1056/NEJMoa2107519

4. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021;398(10295):143-155.

5. Ludvik B, Frias JP, Tinahones FJ, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin (SURPASS-3). Lancet. 2021;398(10300):583-598.

6. Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021;398(10313):1811-1824.

7. Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes (SURPASS-5). JAMA. 2022;327(6):534-545.

8. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.

9. Vadher K, Patel H, Mody R, et al. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022;21(1):169. https://pmc.ncbi.nlm.nih.gov/articles/PMC9438179/

10. Ma Z, Liu X, Ilyas I, et al. Research progress on the GIP/GLP-1 receptor coagonist tirzepatide, a rising star in type 2 diabetes. Front Pharmacol. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10122586/

11. Khashayar F, Preeti P. Tirzepatide. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2024. https://www.ncbi.nlm.nih.gov/books/NBK585056/

12. Wilson JM, Nikooienejad A, Dutta S, et al. The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes. Diabetes Obes Metab. 2022;24(1):148-153.

13. Taktaz F, Scisciola L, Fontanella RA, et al. Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide. Cardiovasc Diabetol. 2024;23(1):242.

14. Liang J, Zhang H, Chen Q, et al. Exploring the molecular mechanisms of tirzepatide in alleviating metabolic dysfunction-associated fatty liver in mice through integration of metabolomics, lipidomics, and proteomics. Lipids Health Dis. 2025;24(1):8.

15. Insights into the mechanism of action of tirzepatide: a narrative review. Diabetes Ther. 2025. https://link.springer.com/article/10.1007/s13300-025-01804-w

16. Sun Y, et al. Tirzepatide in Chinese adults with obesity or overweight: a 52-week randomized controlled trial. [Full citation available in primary source; included in Palmetto Peptides extended reference library.]

17. Pahlavani M, et al. The promise of tirzepatide: a narrative review of metabolic benefits. [ScienceDirect, 2025.] https://www.sciencedirect.com/science/article/pii/S1751991825000816

18. Osei-Bonsu A, et al. Unveiling tirzepatide's therapeutic spectrum: a dual GIP/GLP-1 agonist targeting metabolic, neurological, and cardiovascular health. PMC. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12507501/

---

Research Use Disclaimer: Tirzepatide and all other peptides offered by Palmetto Peptides are intended exclusively for in vitro laboratory research by qualified scientific professionals. These products are not approved for human or veterinary use, are not dietary supplements, and are not medications. They have not been evaluated by the FDA for safety or efficacy in humans or animals outside of regulated pharmaceutical contexts. Palmetto Peptides makes no medical claims and does not recommend or encourage the use of any research peptide outside of properly licensed and controlled laboratory settings. By purchasing from Palmetto Peptides, buyers confirm that they are qualified researchers who will use products in compliance with all applicable local, state, and federal laws and regulations.

---

Palmetto Peptides Research Team

Last Updated: March 19, 2025